Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Alcobra, Ltd. (“Alcobra” or the “Company”) (Nasdaq: ADHD). Investors, who purchased or otherwise acquired shares between August 13, 2015 and January 17, 2017 inclusive (the "Class Period"), are encouraged to contact the Firm within 60 days of this notice.

If you purchased shares of Alcobra during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Alcobra is a biopharmaceutical company that makes and markets oral drug candidates. On January 17, 2017, Alcobra disclosed that the Company's attention deficit hyperactivity disorder drug, Metadoxine Extended Release, could not reach its primary endpoint during a Phase 3 trial. When this information was disclosed to the public, the value of Alcobra declined, causing investors harm.

If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.